Last 18 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Indivior Pharmaceuticals Inc's quarterly P/E stands at 11.0x, up 76.1% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 64.1% YoY to 6.8x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 24.15 | 11.04 | 10.94 | 18.27 | 26.32 | 6.27 | 6.91 | 81.25 | — | 11.90 | 10.05 | — | 21.25 |
| — | +76.1% | +58.4% | -77.5% | — | -47.3% | -31.3% | — | — | -9.1% | — | — | +51.6% | |
| P/S Ratio | 3.99 | 3.10 | 3.13 | 2.48 | 1.51 | 1.11 | 1.33 | 1.06 | 1.82 | 2.62 | 1.85 | 2.93 | 3.08 |
| — | +179.9% | +135.3% | +133.5% | -17.0% | -57.6% | -28.0% | -63.8% | -40.9% | +12.0% | -39.7% | +23.8% | +5.3% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | 297.34 | — | — | 29.03 |
| — | — | — | — | — | — | — | — | — | +806.0% | — | — | +159.0% | |
| P/FCF | — | — | — | — | 3.07 | 4.21 | — | — | 6.48 | — | — | 41.53 | — |
| — | — | — | — | -52.6% | — | — | — | — | — | — | +336.5% | — | |
| EV / EBITDA | 17.88 | 6.80 | 9.14 | 7.26 | 5.45 | 4.14 | 4.08 | 19.09 | — | 9.38 | 7.62 | — | 11.51 |
| — | +64.1% | +124.0% | -62.0% | — | -55.8% | -46.5% | — | — | +15.1% | — | — | +58.4% | |
| EV / EBIT | 19.23 | 6.90 | 9.51 | 7.63 | 5.45 | 4.14 | 4.08 | 36.06 | — | 9.15 | 7.62 | — | 10.72 |
| — | +66.5% | +133.1% | -78.8% | — | -54.7% | -46.5% | — | — | +21.2% | — | — | +38.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Indivior Pharmaceuticals Inc's operating margin was 43.2% in Q1 2026, up 9.1 pp QoQ and up 18.4 pp YoY. This marks the 4th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 33.2% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 4.7% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.1% | 87.4% | 82.1% | 80.3% | 82.8% | 83.5% | 92.3% | 77.5% | 73.6% | 86.6% | 82.6% | 83.0% | 81.9% |
| — | +4.7% | -11.0% | +3.5% | +12.5% | -3.6% | +11.8% | -6.6% | -10.1% | +2.4% | +0.9% | +0.3% | -1.1% | |
| Operating Margin | 21.4% | 43.2% | 34.1% | 31.5% | 23.8% | 24.8% | 32.1% | 1.3% | -39.5% | 26.4% | 20.8% | -67.5% | 22.1% |
| — | +74.2% | +6.1% | +2319.9% | +160.4% | -6.0% | +54.2% | +101.9% | -278.6% | +17.2% | +119.5% | -379.8% | -22.5% | |
| Net Margin | 16.9% | 28.1% | 28.5% | 13.4% | 6.0% | 17.7% | 19.7% | 1.3% | -32.4% | 21.5% | 18.4% | -49.8% | 14.1% |
| — | +58.9% | +44.4% | +926.6% | +118.4% | -17.7% | +7.1% | +102.6% | -329.6% | +23.5% | +124.4% | -381.9% | -34.9% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | 610.5% | — | -290.3% | 41.3% |
| — | — | — | — | — | — | — | — | — | +755.2% | — | -1719.8% | +98.8% | |
| ROA | 16.6% | 7.4% | 7.8% | 2.9% | 1.3% | 3.5% | 4.2% | 0.3% | -6.5% | 3.8% | 3.0% | -7.5% | 2.2% |
| — | +112.5% | +83.6% | +998.2% | +119.6% | -8.0% | +42.0% | +103.5% | -390.3% | +52.3% | +128.1% | -412.0% | -19.6% | |
| ROIC | 342.7% | — | 157.8% | — | — | — | — | — | — | 137.3% | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Indivior Pharmaceuticals Inc's Debt/EBITDA ratio is 0.2x, down from 2.8x last quarter — comfortably within a safe range.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | 27.90 | — | — | 2.40 |
| — | — | — | — | — | — | — | — | — | +620.0% | — | — | +97.3% | |
| Debt / EBITDA | 1.23 | 0.17 | 2.76 | 3.42 | 4.75 | 5.21 | 3.71 | 16.71 | — | 3.48 | 4.04 | — | 4.19 |
| — | -96.8% | -25.6% | -79.5% | — | +49.5% | -8.2% | — | — | -21.3% | — | — | +3.1% | |
| Current Ratio | 0.71 | 0.86 | 0.71 | 0.96 | 0.90 | 0.88 | 0.89 | 0.83 | 0.85 | 0.92 | 0.98 | 0.98 | 1.13 |
| — | -2.5% | -20.2% | +15.0% | +5.5% | -5.0% | -9.0% | -15.7% | -24.1% | -14.1% | -20.6% | -42.0% | -33.9% | |
| Quick Ratio | 0.55 | 0.66 | 0.55 | 0.79 | 0.76 | 0.72 | 0.70 | 0.65 | 0.68 | 0.74 | 0.88 | 0.87 | 0.99 |
| — | -7.7% | -22.4% | +22.8% | +10.9% | -2.6% | -19.7% | -25.8% | -30.9% | -23.2% | -22.0% | -44.1% | -37.2% | |
| Interest Coverage | 6.31 | 19.57 | 20.33 | 8.25 | 5.13 | 5.92 | 7.77 | 0.90 | -12.44 | 10.25 | 7.78 | -17.10 | 7.20 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 18 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying INDV stock.
Indivior Pharmaceuticals Inc's current P/E is 24.1x. The average P/E over the last 4 quarters is 16.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Indivior Pharmaceuticals Inc's current operating margin is 21.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Indivior Pharmaceuticals Inc's business trajectory between earnings reports.